Lilly Wins FDA Approval for Once-Weekly Insulin Efsitora

The FDA has approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s once-weekly basal insulin for adults with type 2 diabetes, making it the second such agent cleared in the US and setting up a direct contest with Novo Nordisk’s insulin icodec-abae (Awiqli).

A flat geometric editorial illustration showing the journey of a drug through regulatory approval stages, with human figures at key checkpoints along a pipeline corridor against a deep navy background.

PHARMA REGULATION · DIABETES APPROVAL · SEPTEMBER 26, 2026 · USA

Two once-weekly basal insulins now compete in the United States. The FDA approved insulin efsitora alfa-gobe (Onswik), Eli Lilly’s long-acting insulin analog, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM), according to Lilly. It is the second once-weekly basal insulin cleared for US use, after Novo Nordisk’s insulin icodec-abae (Awiqli), which received FDA approval on March 26, 2026, per Novo Nordisk.

The clinical case rests on non-inferiority, not superiority. Lilly evaluated efsitora in four randomised, open-label, active-controlled studies covering insulin-naive adults with T2DM, adults previously on once- or twice-daily basal insulin, and adults previously on basal plus mealtime insulin, according to Lilly. Across all four studies, efsitora reduced haemoglobin A1c — a measure of average blood glucose over time — to a similar extent compared with once-daily insulin glargine and insulin degludec. The QWINT-1, QWINT-3, and QWINT-4 trials, which Lilly funded, provided the detailed readouts: in QWINT-1, efsitora reduced A1c by 1.31% versus 1.27% for insulin glargine at 52 weeks; in QWINT-3, by 0.86% at week 26 versus 0.75% for insulin degludec; in QWINT-4, by 1.07% at week 26, matching insulin glargine, according to Fierce Pharma. These trials met their primary non-inferiority endpoints; the design did not test whether efsitora is superior to daily basal insulin.

The safety profile follows the class pattern. Lilly lists hypoglycaemia as the most common adverse reaction, with additional warnings covering hypersensitivity reactions, injection-site reactions, lipodystrophy, pruritus, rash, oedema, and weight gain. Lilly states that efsitora is not recommended for people with type 1 diabetes because of an increased risk of severe hypoglycaemia — a label restriction that bounds the addressable population to T2DM adults.

A two-supplier market takes shape

Kenneth Custer, Eli Lilly’s Executive Vice President and President of Lilly Cardiometabolic Health, is named in the company’s press materials as the executive associated with the launch, per PRNewswire. No US list price or wholesale acquisition cost for efsitora has been publicly disclosed; the company has not detailed launch timing or commercial terms beyond the approval itself. For context on the competitive pricing environment, Novo Nordisk priced Awiqli’s once-weekly 70-unit dose at 261 rupees ($2.74) at its India launch in July 2026, according to Reuters — though Indian launch pricing is not directly comparable to US commercial or Medicare pricing, and Awiqli’s US pricing has not been reported in the available record.

The arrival of a second once-weekly agent in the same dosing-frequency class may give payers formulary leverage they did not have when Awiqli stood alone. A two-supplier market historically enables payers to extract competing rebate offers, though the pace and magnitude of any net-price compression will depend on how aggressively each manufacturer pursues formulary position — a negotiation that has not yet been publicly disclosed for either product. No analyst estimate of peak sales or market share for efsitora has been published in the available record.

The more immediate competitive pressure may fall on the daily basal insulin franchises — insulin glargine and insulin degludec — rather than on Awiqli alone. Efsitora’s label covers the same patient populations that currently use daily basal insulin, and Lilly’s own trial programme was designed to demonstrate equivalence against those daily agents. If once-weekly dosing becomes a formulary standard across both commercial and Medicare plans, the incumbents defending daily-injection market share face a substitution argument that two approved once-weekly agents make structurally harder to resist.

Global access: NICE recommends, UK regulator has not yet decided

Outside the US, the picture is asymmetric. The National Institute for Health and Care Excellence (NICE), the UK’s drug cost assessor, issued final draft guidance recommending efsitora for coverage on the National Health Service (NHS), according to Fierce Pharma. The recommendation is based on QWINT-1, QWINT-3, and QWINT-4 data showing non-inferior A1c reduction versus daily insulin. A Lilly spokesperson told Fierce Pharma that the company is ‘awaiting a decision from the MHRA on marketing authorization’ — meaning NHS coverage, while recommended, cannot be activated until the Medicines and Healthcare products Regulatory Agency (MHRA) grants a marketing authorisation. A recommendation is not a dispensed prescription.

NICE’s guidance notes that once-weekly dosing could be particularly valuable for people who need assistance with injections because of sight loss, frailty, limited hand movement, or difficulty following multi-step administration procedures, and that the reduced injection burden could lower dependence on caregivers and healthcare workers. Awiqli is already approved in the European Union and several other countries and launched in India in July 2026, per Reuters, while Onswik is already approved by the EMA, Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), per Lilly.

In Mexico, Lilly’s press materials note a COFEPRIS approval for Onswik, per PRNewswire. No filing or approval status for efsitora at Brazil’s Agência Nacional de Vigilância Sanitária (ANVISA), Argentina’s Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) or Colombia’s Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) has been disclosed in the available record.

The principal friction on the US commercial side is reimbursement timing. Medicare Part D formulary cycles and commercial plan formulary updates operate on annual schedules, meaning an approval issued in mid-year may not translate into broad covered access until the next plan year. People with T2DM who could benefit from reduced injection frequency — Lilly’s press materials describe a reduction of more than 300 injections per year versus once-daily basal insulin — may face a gap between regulatory clearance and actual formulary availability. The size of that gap depends on whether payers treat efsitora as a preferred agent, a non-preferred alternative, or a step-therapy requirement behind existing daily basal insulins, none of which has been disclosed.

What to Watch

  1. US list price and Medicare Part D formulary placement for efsitora, and whether Lilly and Novo Nordisk engage in competing rebate negotiations with major pharmacy benefit managers
  2. MHRA marketing authorisation decision for efsitora in the UK, which would activate the NICE NHS coverage recommendation
  3. ANVISA, ANMAT, and INVIMA filing timelines for efsitora in Brazil, Argentina, and Colombia — none has been publicly confirmed
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper structural signal is that the once-weekly basal insulin class has moved from a single-entrant novelty to a two-product competitive segment within months. That transition shifts the negotiating dynamic: payers who previously had no alternative to Awiqli now have one, and the daily basal insulin manufacturers defending the largest installed base face pressure from both sides of the dosing-frequency argument simultaneously.

Clinical Profile and Market Access

A1c Reduction vs Insulin Glargine

1.31%

QWINT-1, 52 weeks

Injection Reduction vs Once-Daily Basal

300+

Injections per year

Regulatory Status: FDA approval confirmed (September 2026); also approved by the EMA, COFEPRIS and PMDA, per Lilly. NICE final draft guidance recommending efsitora for NHS coverage issued (August 2026).

Sources: Fierce Pharma (Lilly clinical data, June 2026); PRNewswire / Lilly company guidance (2026); Fierce Pharma (NICE guidance, August 2026)

Why this is relevant

Patients

Adults with type 2 diabetes who require assistance with injections due to sight loss, frailty, or limited hand movement may benefit most from the shift to once-weekly dosing; Lilly’s press materials describe a reduction of more than 300 injections per year versus once-daily basal insulin, though US formulary availability depends on payer decisions not yet disclosed.

Industry

Eli Lilly’s approval converts the once-weekly basal insulin segment from a single-entrant market into a two-supplier contest; the more immediate competitive pressure may fall on daily insulin glargine and degludec franchises, which now face a substitution argument supported by two approved once-weekly alternatives.

Payers

The presence of two once-weekly basal insulins may create formulary leverage for Medicare Part D plans and commercial insurers, though rebate structures and preferred-tier placements have not been disclosed; annual formulary cycles suggest broad covered access may not activate until the next plan year.

Caregivers

NICE’s final draft guidance explicitly notes that once-weekly dosing could reduce caregiver and healthcare-worker dependence for people with type 2 diabetes who need injection assistance, a finding that suggests the clinical benefit extends beyond the patient to those providing daily support.

Sources: Eli Lilly and Company · Novo Nordisk · Nursing in Practice · Fierce Pharma · Reuters

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related